News

Public · Published

Guggenheim maintains AbbVie at Buy, raises price target to $322 from $288

Guggenheim kept its Buy rating on AbbVie and raised its price target to $322 from $288, an 11.8% increase. The new target implies 9.2% upside from AbbVie's Oct. 30 closing price of $294.89. Five recent analyst targets listed range from $294 to $340.

Published:

Updated:

What happened

Guggenheim kept its Buy rating on AbbVie and raised its price target to $322 from $288, an 11.8% increase. The new target implies 9.2% upside from AbbVie's Oct. 30 closing price of $294.89. Five recent analyst targets listed range from $294 to $340.

Confirmed

Global impact / market context

A higher target signals that Guggenheim sees more potential value in AbbVie shares, but it is an analyst estimate, not a promised return. If investors act on the view, increased demand could support the share price; the article gives no evidence of an actual market reaction.

Analyst inference

Recent opinions are mixed: the listed targets span $294 to $340, while ratings include Buy, Overweight, Outperform, and Neutral. The range shows analysts do not share one valuation, and the $322 target sits within that spread rather than establishing a consensus.

Confirmed

What to watch

  1. Compare upcoming analyst targets and ratings with the current $294–$340 range to see whether views on AbbVie are converging or diverging. Analyst inference
  2. Check whether subsequent company results or outlook updates support assumptions behind higher targets; this article provides no operating results or reasons for Guggenheim's change. Analyst inference
  3. Track AbbVie's share price against Guggenheim's $322 target and its stated 9.2% implied upside from the Oct. 30 close. Analyst inference

Evidence

  • Original source link unavailable